Conditions: Platinum Sensitive; BRCA Mutated; Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Drug: Olaparib 300mg tablets; Drug: Placebo to match olaparib 300mg
Sponsors: AstraZeneca; European Network of Gynaecological Oncological Trial Groups (ENGOT); Myriad Genetic Laboratories, Inc.; Merck Sharp & Dohme LLC
Active, not **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
